{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=11",
    "query": {
      "intervention": "Injectable saline",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 2099,
    "total_pages": 210,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Injectable+saline&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T02:40:54.112Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01767519",
      "title": "A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "BOTOX®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "solifenacin",
          "type": "DRUG"
        },
        {
          "name": "Botox placebo (normal saline)",
          "type": "DRUG"
        },
        {
          "name": "solifenacin placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2013-03-01",
      "completion_date": "2015-03-18",
      "has_results": true,
      "last_update_posted_date": "2019-04-23",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01767519"
    },
    {
      "nct_id": "NCT05428007",
      "title": "Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab/Relatlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 105,
      "start_date": "2023-02-02",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05428007"
    },
    {
      "nct_id": "NCT01153581",
      "title": "Sex Hormones and Orthostatic Tolerance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Orthostatic Intolerance"
      ],
      "interventions": [
        {
          "name": "Ganirelix acetate",
          "type": "DRUG"
        },
        {
          "name": "17β-Oestradiol",
          "type": "DRUG"
        },
        {
          "name": "Progesterone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "34 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 34 Years · Female only"
      },
      "enrollment_count": 109,
      "start_date": "2006-02",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153581"
    },
    {
      "nct_id": "NCT04655339",
      "title": "Laparoscopic Transversus Abdominis Plane (TAP) Block to Reduce Post-operative Opioids",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use"
      ],
      "interventions": [
        {
          "name": "Bilateral abdominal Lap-TAP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-01-24",
      "completion_date": "2021-09-03",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655339"
    },
    {
      "nct_id": "NCT05003765",
      "title": "Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Post-operative Pain Management"
      ],
      "interventions": [
        {
          "name": "Bupivacaine 0.25% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2020-08-06",
      "completion_date": "2022-05-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 1,
      "location_summary": "Pontiac, Michigan",
      "locations": [
        {
          "city": "Pontiac",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05003765"
    },
    {
      "nct_id": "NCT06097299",
      "title": "A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "mRNA-1345",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 349,
      "start_date": "2023-10-24",
      "completion_date": "2025-06-27",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097299"
    },
    {
      "nct_id": "NCT01926028",
      "title": "Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Vulvovaginal Candidiasis"
      ],
      "interventions": [
        {
          "name": "NDV-3A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NDV-3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NovaDigm Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 188,
      "start_date": "2013-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926028"
    },
    {
      "nct_id": "NCT06651177",
      "title": "Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Use Disorder, Moderate",
        "Opioid Use Disorder, Severe"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "T. John Winhusen, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2026-01-29",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 9,
      "location_summary": "Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cape Girardeau",
          "state": "Missouri"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06651177"
    },
    {
      "nct_id": "NCT02084628",
      "title": "Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Magnetic Resonance Imaging"
      ],
      "interventions": [
        {
          "name": "Gadoxetate disodium (Eovist/Primovist, BAY86-4873)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "2 Months",
        "sex": "ALL",
        "summary": "Up to 2 Months"
      },
      "enrollment_count": 1,
      "start_date": "2015-02",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02084628"
    },
    {
      "nct_id": "NCT06411067",
      "title": "Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United States Naval Medical Center, Portsmouth",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 0,
      "start_date": "2020-02-26",
      "completion_date": "2022-05-09",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-23T02:40:54.112Z",
      "location_count": 1,
      "location_summary": "Portsmouth, Virginia",
      "locations": [
        {
          "city": "Portsmouth",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411067"
    }
  ]
}